Dismissed members of CDC vaccine committee call Kennedy's actions ‘destabilizing'
NEW YORK — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions' made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread.
Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings.
Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation.
'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Assn.
The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria.
In addition to Wharton's removal, CDC immunization staff have been cut and agency experts who gather or present data to committee members have resigned.
One, Dr. Lakshmi Panagiotakopoulos, resigned after 12 years at CDC, disclosing her decision early this month in a note to members of a COVID-19 vaccines work group. Her decision came after Kennedy decided — without consulting the vaccine advisers — to pull back COVID-19 vaccination recommendations for healthy children and pregnant women.
'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in a message viewed by the Associated Press.
Those CDC personnel losses will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about which vaccines to recommend to the public, the former committee members said.
'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote.
A spokesperson for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee.
Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines.
The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs.
ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
Stobbe writes for the Associated Press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
6 hours ago
- Los Angeles Times
Dismissed members of CDC vaccine committee call Kennedy's actions ‘destabilizing'
NEW YORK — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions' made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread. Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings. Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation. 'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Assn. The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria. In addition to Wharton's removal, CDC immunization staff have been cut and agency experts who gather or present data to committee members have resigned. One, Dr. Lakshmi Panagiotakopoulos, resigned after 12 years at CDC, disclosing her decision early this month in a note to members of a COVID-19 vaccines work group. Her decision came after Kennedy decided — without consulting the vaccine advisers — to pull back COVID-19 vaccination recommendations for healthy children and pregnant women. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in a message viewed by the Associated Press. Those CDC personnel losses will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about which vaccines to recommend to the public, the former committee members said. 'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote. A spokesperson for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee. Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak. Stobbe writes for the Associated Press.
CBS News
7 hours ago
- CBS News
CDC official overseeing COVID hospitalization data resigns after RFK Jr.'s vaccine orders
A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from infectious diseases like COVID-19 has resigned in protest following Health and Human Services Secretary Robert F. Kennedy Jr.'s orders to change the agency's vaccine recommendations and the committee that makes them. Dr. Fiona Havers' last day at the CDC was Monday, according to an announcement sent by an agency official to her branch within the agency's Coronavirus and Other Respiratory Viruses Division. They received the notice shortly after Reuters first reported on the resignation. "I no longer have confidence that these data will be used objectively or evaluated with appropriate scientific rigor to make evidence-based vaccine policy decisions," Havers wrote in an email sent to colleagues before the announcement. An infectious disease researcher who has worked with Havers, and received her email voicing concerns with how the data would be used, described the resignation as the latest in the "dismantling" of the agency's expertise. "It's a big loss to the CDC," the researcher, who spoke on the condition of anonymity, told CBS News. CBS News sent a request for comment to the CDC about the concerns that Havers expressed, but did not hear back from the agency's spokesperson. Instead, a spokesperson for the Department of Health and Human Services responded. "Under Secretary Kennedy's leadership, HHS is committed to following the gold standard of scientific integrity. Vaccine policy decisions will be based on objective data, transparent analysis, and evidence – not conflicts of interest or industry influence," Emily Hilliard, the department spokesperson, said in an email. Havers had led the CDC's Respiratory Virus Hospitalization Surveillance Network, or RESP-NET, that collects and studies trends in hospitalizations from COVID-19, RSV and influenza. Her presentations of RESP-NET's findings have figured prominently into past meetings of the agency's Advisory Committee of Immunization Practices as they weighed updates to the CDC's vaccine recommendations. "Of all the work we have accomplished, I am most proud of how COVID-NET and RSV-NET hospitalization data, presented at nearly every public ACIP meeting since 2020, have been critical drivers of COVID-19 and RSV vaccine policy in recent years," Havers wrote in her email. The CDC's vaccine recommendations are closely watched by doctors and health authorities because they are tied to federal policies enabling access to vaccines, including liability protections and requirements for insurance coverage. Usually, the ACIP deliberates and votes on updated recommendations, which are later adopted by the CDC director. In an unprecedented move this year, Kennedy bypassed the process to order his own changes. In late May, Kennedy first ordered narrowing the guidance to exclude children and pregnant women without other underlying health conditions, sidestepping an ACIP process that had been already underway to discuss changing the recommendations. He then fired the current roster of ACIP members in June — in what he described as a "clean sweep" of the panel — as well as removed the agency officials who oversee the panel's vetting and agenda. In a viewpoint published Monday in the Journal of the American Medical Association, the 17 members of the panel fired by Kennedy denounced the health secretary for "dismantling the process by which vaccines have been recommended." "As former ACIP members, we are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of US immunization policy, impact people's access to lifesaving vaccines, and ultimately put US families at risk of dangerous and preventable illnesses," they wrote. Kennedy later replaced the panel with a list of picks that included several allies of the health secretary and opponents of recommendations for COVID-19 and some other vaccines. The committee's new membership is set to meet next week to vote on updated vaccine recommendations for COVID-19 and RSV, among other diseases.
